Skip to content

Psilocybin: all studies

Page 311 of 439: studies 3,101 to 3,110 of 4,389, newest first. Back to the psilocybin overview

Research

Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health.

Drug and Alcohol Dependence May 1, 2026 Juan Carlos C. Montoy, Ralph C. Wang, Allison R. Coker et al.

Psychedelic drug use is increasing due in part to local legislative reforms. Understanding the patterns of first-time psychedelic drug use is imperative for informing consumers, healthcare providers, and policy makers. The National Survey on Drug Use and Health (NSDUH) is a repeated cross-sectional nationally representative survey of civilians aged 12 and older. Use estimates are presented for...

Psychological support in psychedelic-assisted therapy clinical trials: A systematic review.

Journal of Psychopharmacology May 1, 2026 Bonnie Brusky, Katia M'Bailara, François Alla et al.

The nature and role of the psychological support provided in psychedelic-assisted treatments for psychiatric disorders are currently the object of debate. How this support is conceptualized-as a vector for therapeutic change or framework for risk minimization-has far-reaching consequences in terms of how these treatments should be regulated, delivered, and studied. To determine whether...

New Approach Methodologies and Open Access Tools Help Characterize Risks for DART, DNT, or Endocrine Effects From Exposure to Hallucinogens With Potential Pesticide Contaminants.

Birth defects research May 1, 2026 Marilyn H Silva

Psilocybe mushrooms (psilocybin/psilocin [PSI/PSC]) and ayahuasca (N,N-dimethyltryptamine [DMT]) are hallucinogenic serotonergic agonists. Pregnant and lactating women are frequently omitted from clinical studies; hence minimal developmental/reproductive/neurotoxicity (DART/DNT) and endocrine disruption (ED) data in humans are available. Hallucinogens contaminated with pesticides may have...

DOI: 10.1002/bdr2.70048 (opens in new tab) Full text (opens in new tab) Predpreg Toxcast Cheminformatics Hallucinogens +3

The Ecstasy of Gold in Neurodiversity: Focus on the Use of Psychedelics in Autism Spectrum Disorder

Preprints.org April 29, 2026 Stefano Marini, Domenico de Berardis preprint

Psychedelic drugs are serotonergic hallucinogens that can be divided into two types: naturally occurring (psilocybin, psilocin, and N,N-dimethyltryptamine) and synthetic (LSD, MDMA, 2,5-dimethoxy-4-iodoamphetamine, and ketamine). Psychedelics generally work on 5-hydroxytryptamine receptors and might be useful in cognitive enhancement, brain connectivity, neuroplasticity, and neuronal...

DOI: 10.20944/preprints202604.1998.v1 (opens in new tab) Addiction Autism spectrum disorder Hallucinogen Psychopathology +4

Back to our roots: Integrating wholistic research approaches in the study of medicinal plants and mushrooms

Psychopharmacology April 24, 2026 Melissa L. Perreault, T. Ryan Gregory, Andrew Maxwell Phineas Jones

Whole plants and mushrooms have been used in systems of traditional medicine and health around the globe for millennia, and these more wholistic approaches are increasingly being embraced in modern Western societies. Cannabis and psilocybin are perhaps two of the most salient examples given current public and academic interests. Greater accessibility, along with expanding socioeconomic and...

DOI: 10.1007/s00213-026-07075-y (opens in new tab) Full text (opens in new tab) Medicinal plants Identification biology Traditional knowledge Medicinal fungi +2

Classic psychedelic and cannabis use among U.S. cancer survivors aged ≥ 50 years: nationally representative estimates by cancer type/site.

Cancer causes & control : CCC April 22, 2026 Amrit Baral, Yue Pan, Wayway M. Hlaing et al.

To examine the prevalence of lifetime ("ever") cannabis and classic psychedelic use, and their co-use among U.S. adults aged ≥ 50 years with versus without a lifetime history of cancer, and to describe variation by cancer type/site among survivors. We analyzed pooled 2015-2019 and 2021-2022 National Survey on Drug Use and Health (NSDUH) data of U.S. adults aged ≥ 50 years (Unweighted; n =...

Serotonergic Polypharmacology of 2-Halogenated Tryptamines.

bioRxiv : the preprint server for biology April 21, 2026 Jeanine Yacoub, Elena Bray, Jude Bayyat et al. preprint

Serotonergic psychedelics such as N,N-dimethyltryptamine (DMT) and 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) show therapeutic promise for psychiatric and neurodegenerative disorders but may be limited by liabilities from serotonin (5-HT)-2A mediated psychoactive effects and potential cardiotoxicity via 5-HT2B activation. To address these limitations, we designed and synthesized...

Psychedelics: Historical Context, Emerging Science, and Future Clinical Frontiers

Journal of Mental Health Disorders April 18, 2026 Vipul Janardan, Amit Khanna, Om Prakash et al.

Psychedelics a class of psychoactive compounds such as psilocybin, lysergic acid diethylamide (LSD), and dimethyltryptamine (DMT) are undergoing a scientific renaissance. Studies since 2020 have shown their therapeutic promise in mental health treatment. This Commentary synthesizes historical usage, current neuroscientific and clinical evidence, and explores ethical and regulatory frontiers for...

Psychedelics and Autism Therapy: A Review of Current Research and Future Directions

Current Issues in Molecular Biology April 18, 2026 Christopher S. Gondi, Manu Gnanamony, Tarun P. Gondi et al.

Autism Spectrum Disorder (ASD) is a lifelong condition marked by challenges in social communication and repetitive behaviors. Current treatments, primarily behavioral therapies, often fail to address the core symptoms. Recent research has explored the potential of psychedelics, such as LSD, psilocybin, and MDMA, as a new therapeutic approach. While these substances primarily modulate the...

DOI: 10.3390/cimb48040417 (opens in new tab) Neuroplasticity Glutamatergic Autism spectrum disorder Therapeutic approach +2

Producción de alcaloides en Psilocybe cubensis: aportes desde la bioquímica del Triptófanoy la sustentabilidad

CIENCIA EN DESARROLLO April 16, 2026 Brenda M. Delgado Melgarejo, Gerardo A. Caicedo

Esta revisión analiza cómo la suplementación con L-triptófano en el sustrato de cultivo de Psilocybe cubensis potencia la biosíntesis de psilocibina vía las enzimas PsiD, PsiH, PsiK y PsiM, alcanzando aumentos significativos en laconcentración alcaloide respecto a controles sin suplemento.La psilocibina después de ser ingerida se convierte en psilocina por un proceso de desfosforilación, que...